Galectin Therapeutics Inc (GALT)
2.74
+0.02
(+0.74%)
USD |
NASDAQ |
May 31, 16:00
2.73
-0.01
(-0.36%)
After-Hours: 20:00
Galectin Therapeutics Research and Development Expense (TTM): 31.38M for March 31, 2024
Research and Development Expense (TTM) Chart
Historical Research and Development Expense (TTM) Data
| Date | Value |
|---|---|
| March 31, 2024 | 31.38M |
| December 31, 2023 | 32.13M |
| September 30, 2023 | 32.91M |
| June 30, 2023 | 31.78M |
| March 31, 2023 | 32.48M |
| December 31, 2022 | 31.74M |
| September 30, 2022 | 28.59M |
| June 30, 2022 | 28.60M |
| March 31, 2022 | 26.98M |
| December 31, 2021 | 23.82M |
| September 30, 2021 | 24.33M |
| June 30, 2021 | 22.50M |
| March 31, 2021 | 20.73M |
| December 31, 2020 | 17.98M |
| September 30, 2020 | 15.40M |
| June 30, 2020 | 12.12M |
| March 31, 2020 | 8.965M |
| December 31, 2019 | 7.467M |
| September 30, 2019 | 4.863M |
| June 30, 2019 | 4.865M |
| March 31, 2019 | 4.819M |
| December 31, 2018 | 6.471M |
| September 30, 2018 | 6.281M |
| June 30, 2018 | 8.279M |
| March 31, 2018 | 10.25M |
| Date | Value |
|---|---|
| December 31, 2017 | 11.72M |
| September 30, 2017 | 14.15M |
| June 30, 2017 | 13.94M |
| March 31, 2017 | 14.72M |
| December 31, 2016 | 15.32M |
| September 30, 2016 | 14.81M |
| June 30, 2016 | 15.98M |
| March 31, 2016 | 14.36M |
| December 31, 2015 | 13.11M |
| September 30, 2015 | 12.28M |
| June 30, 2015 | 9.795M |
| March 31, 2015 | 8.789M |
| December 31, 2014 | 8.425M |
| September 30, 2014 | 7.74M |
| June 30, 2014 | 6.953M |
| March 31, 2014 | 6.708M |
| December 31, 2013 | 5.688M |
| September 30, 2013 | 5.295M |
| June 30, 2013 | 5.512M |
| March 31, 2013 | 5.378M |
| December 31, 2012 | 4.527M |
| September 30, 2012 | 4.387M |
| June 30, 2012 | 3.633M |
| March 31, 2012 | 3.709M |
| December 31, 2011 | 3.552M |
R&D Expense Definition
R&D expense is a line item from many companies' income statements.
Research and Development Expense (TTM) Range, Past 5 Years
4.863M
Minimum
Sep 2019
32.91M
Maximum
Sep 2023
21.98M
Average
24.08M
Median
Research and Development Expense (TTM) Benchmarks
| Madrigal Pharmaceuticals Inc | 281.43M |
| Viking Therapeutics Inc | 76.90M |
| 89bio Inc | 147.35M |
| Terns Pharmaceuticals Inc | 65.03M |
| Enanta Pharmaceuticals Inc | 151.11M |